Adequan® i.m. Polysulfated Glycosaminoglycan (PSGAG)
INDICATIONS
Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative
and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.
Studies have not been conducted to establish safety in breeding horses.
WARNING: Do not use in horses intended for human consumption. Not for use in humans.
Keep this and all medications out of the reach of children.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
For full prescribing information,
click here.
BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension)
For Intra-articular (I.A.) use in Horses.
INDICATIONS
BetaVet® is indicated for the control of pain and inflammation associated with osteoarthritis in horses.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS:
BetaVet® is contraindicated in horses with hypersensitivity
to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis.
WARNINGS: Do not use in horses intended for
human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition
when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.
Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted congenital anomalies. Before use of corticosteroids in pregnant animals,
the possible benefits should be weighed against potential hazards.
Human Warnings: Not for use in humans. Keep this and all medications out of the reach of children.
PRECAUTIONS: Corticosteroids, including BetaVet®, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. Acute moderate
to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process.
Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked. Due to the potential for exacerbation of clinical signs
of laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use with caution in
horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs should
be approached with caution. Consider appropriate wash out times prior to administering additional NSAIDs or corticosteroids.
ADVERSE REACTIONS: Adverse reactions reported
during a field study of 239 horses of various breeds which had been administered either BetaVet® (n=119) or a saline control (n=120) at five percent (5%) and above
were: acute joint effusion and/or local injection site swelling (within 2 days of injection), 15% BetaVet® and 13% saline control; increased lameness (within the first 5 days), 6.7%
BetaVet® and 8.3% saline control; loose stool, 5.9% BetaVet®and 8.3% saline control; increased heat in joint, 2.5% BetaVet® and 5% saline control; and depression, 5.9% BetaVet®
and 1.6% saline control.
SHAKE WELL IMMEDIATELY BEFORE USE. For additional safety information, please see
full prescribing information.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Adequan® Canine Polysulfated Glycosaminoglycan (PSGAG)
INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or
traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION
Adequan
® Canine should not be used in dogs who are hypersensitive to polysulfated glycosaminoglycan (PSGAG) or who have a known or suspected bleeding disorder.
It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea,
and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea
have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated.
Caution: Federal law restricts this drug to use by or on the
order of a licensed veterinarian. For additional safety information,
please see
full prescribing information.